quote:Originally posted by BULListic: Back on its way up....***** PUMP coming soon to a gas station near you
This is not a pump, it's all about stem cells. Stem cells save a lot of lives. It saved my own life recently; I simply would not be here today without it. And now it's about to save a lot of wallets as well. So, if you think this is just a pump well, move on and don't bother us on this board will you!
Pluristem Pre-Clinical Results: Placenta Expanded Cell Therapy Product Increases Umbilical Cord Blood Engraftment up to 500% in Bone Marrow Transplants Monday October 16, 7:31 am ET HAIFA, Israel--(BUSINESS WIRE)--Pluristem Life Systems, Inc. (OTCBB: PLRS - News), a cell therapy company dedicated to the commercialization of stem cell products, announces promising final results of an animal model study which could benefit 100,000 blood cancer patients annually. PLX-I, the Company's innovative adjuvant cell therapy product is based on Placenta Expanded Mesenchymal cells. It intended to resolve the global shortfall of matched tissue for blood cancer patients requiring bone marrow transplantation by improving the engraftment of Umbilical Cord Blood (UCB). The Pre-Clinical results document that adding Pluristem's PLX-I to UCB stem cells during the Bone Marrow Transplant (BMT) human cell engraftment in NOD SCID mice showed up to a 500% increased engraftment after irradiation and Chemotropic treatment.
IP: Logged |
posted
PLRS last week traded 317.8 million shares!!!
It was the most active stock last week and I believe it could become the biggest percentage gainer this week!!!
PLRS finished Friday strong up $0.002 to $0.026.
So many eyes are on PLRS right now!!! Once we break through $0.03 again, this could EXPLODE!!! Monday could be the day!!!!!!
I believe that PLRS will have to file an 8-K this week disclosing that their convertible debentures have been converted.
This will be a major event for shareholders because it will show the investment community that PLRS's debt has been eliminated and there will no longer be a lot of selling pressure on the stock.
PLRS's CEO estimated in my meeting with him Thursday that there are now 240 million shares outstanding after the conversions. This would give PLRS a market cap of only $6.2 million at the current price.
When the convertible debenture agreement was announced on April 3rd, PLRS was trading for $0.08. Now that the selling pressure is gone, I believe we will see PLRS rebound to these levels very quickly.
We could go to $0.08 this week even if we trade just a small fraction of the volume we did last week.
I believe PLRS deserves to be valued substantially higher than $0.08.
Even a price of $0.20 would still give PLRS a market cap of less than $50 million.
PLRS could capture a significant share of the $5 billion commercial bone marrow transplant market.
You cannot put a price on the 105,000 - 120,000 lives PLRS could potentially save each year of blood cancer patients who can't find a matching bone marrow donor.
PLRS's PLX-I will provide for a superior alternative to the standard procedure of bone marrow transplantation using adult stem cells from umbilical cord blood.
Watch PLRS like a hawk this week!!!!! This could become the biggest winner of our lives!!!!!
IP: Logged |
posted
I am definitely in first thing Monday morning! I have been watching this sub-penny gem for a while now and I think it is the right time to get onto the stem cell train.
IP: Logged |
posted
I got in ETIM on sharkster recommendation .
Now ***** and sharkster and a few other groups jumpin in on PLRS on monday. www.thesharkster.8m.com is the site , i cant wait to see what happens
IP: Logged |
posted
There is reason for PLRS to go higher with the recent news and upcoming presentation at Bio Europe. Most notably, the 424B4 filing reveals that 1/3 of the shares recently registered are underlying purchase warrants at 0.075 and 0.077 per share.
The company will receive the proceeds from the exercise of these warrants free and clear and has every incentive to do so, whereas the proceeds from the resale of common stock went to the selling security holders, removing overhanging debt. Fullfilling the obligations to the CD holders was the first step in setting the stage to move forward. Once PLRS reaches the 0.10 area, approximately $4,349,881.00 will be added to the company's working capital, as per the filing I will make referrence to.
This would be where many would expect the PPS to head towards, based on how these financings work. The timing of recent news and upcoming presentations suggests that this financing is being well executed.
When reading the disclaimers from Shazaam and *****, we see that they were not compensated by the company itself, but by one of the selling security holders, Zegal & Ross Capital, a total of $50k cash and no shares. The filings reveal that Zegal & Ross only directly hold 1.4 million shares. Since ***** wasn't compensated in shares, he has little reason to keep promoting PLRS unless he has reason to believe it's going much higher. He is putting his reputation and livelihood at stake.
Ask yourselves how high PLRS would need to go to make money on 1.4 million shares after paying out $50k.....The answer is it would have to be a multi bagger from here.
The options granted to management are at 0.10 per share indicating we won't see any sales from then for quite some time. There will be many alerts and talk about PLRS in the coming weeks, and it has been hinted there will be some good news coming from them in the very near term. We will see targets and chatter, but the important indicators are in the filings.
IP: Logged |
posted
Dr. Gyan Parida, Chairman, Global Venture Congress commented, "We are pleased to feature Pluristem as one of our presenting companies at the Global Venture Congress. We consider Pluristem a company that is imminently fundable. They were chosen to be a featured presenting company because of their novel technology, history of raising private capital, and their ability to maximize the capital raised by bringing adult stem cells to the Phase I/II development stage. Very impressive and commendable, Pluristem has passed our rigorous screening process."
posted
It is unbelievable PLRS is trading for only $0.026!!!
PLRS has millions in cash and after the recent conversions they now have no debt!!!
PLRS's CEO estimates PLRS now has 240 million shares outstanding giving it a market cap of only $6.2MM. PLRS's CEO believes it will become a BILLION dollar company one day.
PLRS was the most active stock in the entire market last week and look how strong it closed on Friday!!!
Bone marrow transplants are needed for those suffering from leukemia, lymphoma, myeloma and many other hematological diseases. Unfortunately, 105,000 to 120,000 patients die each year because they can't find a matching bone marrow donor.
PLRS's technology could potentially save millions of lives. PLRS's PLX-I has been shown in preclinical trials to increase the engraftment of stem cells from umbilical cord blood by up to 500% in mice.
PLRS is now positioned to begin Phase I clinical trials and could change the clinical process now being used to treat blood cancer. PLRS's PLX-I could allow umbilical cord blood transplants to replace the bone marrow transplants that are used today.
The Israeli government realizes how huge PLRS could become and recently gave the company a $470,000 grant.
The US government also realizes the potential for umbilical cord blood to cure many diseases and just last week announced that they will award about $14 million to public cord blood banks around the country to increase the supply of cord blood donations from 50,000 to 150,000.
The timing couldn't be more perfect for PLRS!!!
So many eyes are on PLRS right now!!! PLRS could EXPLODE this week!!!
IP: Logged |
Today’s Price Performance as of 10:30am EDT, 10/23/2006 Option Chains Margin Requirements Interactive Chart
Loading Chart1 Day | 5 Day | 6 Mo | 1 Yr | 3 Yr | 5 Yr $0.029 Last Price 0.0030 +11.54% Today’s Change $0.03 Today’s Open 10,774,781 Above Avg. Today’s Volume
-------------------- All I say is IMHO.
I like these calm little moments before the storm... Reminds me of Bethoven
IP: Logged |
posted
Press Release Source: Pluristem Life Systems, Inc.
Pluristem Completes the Conversion to Common Stock of 98% of the $3,000,000 in Convertible Debentures Issued on April 3, 2006 Tuesday October 24, 9:00 am ET
HAIFA, Israel--(BUSINESS WIRE)--Pluristem Life Systems, Inc. (OTCBB:PLRS - News) announces they have completed the conversion of 98% of the $3,000,000 in convertible debentures that were issued on April 3, 2006 to common stock of the company. The outstanding common shares are now about 254 million shares. ADVERTISEMENT
Zami Aberman, Pluristem CEO states, "This allows us considerably more financing flexibility because until over 75% of the debentures were converted to common stock, we were prevented from pursuing certain types of financing arrangements and our assets were encumbered as collateral security for repayment of the debentures. Now that the vast majority of the debentures have been converted our assets are no longer encumbered and we are no longer restricted in the type of financing arrangements we can make. In addition, our balance sheet no longer will show the converted debenture proceeds as a liability."
About Pluristem:
Pluristem Life Systems, Inc. is a life-sciences-driven company that is developing and commercializing stem cell expansion technology products for the treatment of severe blood disorders. The Company is discovering and developing cell-based therapeutics that utilizes adult stem cells expanded in a proprietary bioreactor mimicking different naturally occurring physiological environments. Pluristem expects its first products to be cell grafts that will provide an efficient and superior alternative to the standard procedure of bone marrow transplantation. Its first adult stem cell product is intended to target a critical global shortfall of matched tissue for bone marrow transplantation since bone marrow transplantation is often the only cure for patients suffering from leukemia, lymphoma, myeloma and many other hematological diseases. The Company has made a strategic decision to work only with adult stem cells since the practical use of embryonic stem cells is severely restricted by various religious, ethical and legal considerations.
This press release contains statements, which may constitute "forward-looking statements" regarding our intent, belief or current expectations. Forward-looking statements in this release include statements: that PLX-I can be used for the treatment of blood disorders ; that we expect our first products to be cell grafts that will provide an efficient and superior alternative to the standard procedure of bone marrow transplantation, and our first adult stem cell product is intended to target a critical global shortfall of matched tissue for bone marrow transplantation. Factors which may significantly change or prevent our forward looking statements from fruition include that we may be unsuccessful in developing any products; that our technology may not be validated as we progress further and our methods may not be accepted by the scientific community; that we are unable to retain or attract key employees whose knowledge is essential to the development of our products; that unforeseen scientific difficulties develop with our process; that results in the laboratory do not translate to equally good results in real surgical settings; that our patents are not sufficient to protect essential aspects of our technology; that competitors may invent better technology; that our products may not work as well as hoped or worse, that our products may harm recipients; and that we may not be able raise funds for development or working capital when we require it. As well, our products may never develop into useful products and even if they do, they may not be approved for sale to the public. For further risk factors see the Company's latest 10-KSB filed with the SEC.
Contact: Emerson Gerard Associates, Inc. Jerry Jennings, Media Contact, 561-881-7318 mediareply*emersongerard.com
-------------------------------------------------------------------------------- Source: Pluristem Life Systems, Inc.
-------------------- please dont trade stocks on my alerts, do your dd first.
IP: Logged |
"On October 24, 2006 we announced that over 98% of the $3,000,000 in convertible debentures that we issued on April 3, 2006 have been converted to common stock in our company. This allows us considerably more financing flexibility because until over 75% of the debentures were converted to common stock, we were prevented from pursuing certain types of financing arrangements and our assets were encumbered as collateral security for repayment of the debentures. Now that the vast majority of the debentures have been converted our assets are no longer encumbered and we are no longer restricted in the type of financing arrangements we can make. In addition, our balance sheet no longer will show the converted debenture proceeds as a liability."
What the f*** "considerably more financing flexibility" means? More CDs in the nearest future? Is this the reason of PPS drop or just because l e b e d stops pump it?
IP: Logged |
UBBFriend: Email this page to someone!
Printer-friendly view of this topic
![[Roll Eyes]](rolleyes.gif)
![[Smile]](smile.gif)
